52601
HCPCS/CPT
Prior Authorization
No Prior Auth Required
Code is covered without prior authorization (high confidence)
Medicare Pricing
Work RVU
9.75
Facility
$526.06
Non-Facility
$526.06
Documentation Required
- Laboratory values as applicable (e.g., PSA measurements reported in many trials and used as a secondary outcome).
- Imaging/angiographic documentation for PAE (prostatic arterial anatomy identification) and documentation of technical feasibility or reasons for technical failure.
- Erectile and ejaculatory function assessment (IIEF-5 or IIEF-15, MSHQ, MSHQ-EjD, SHIM) where preservation of sexual function is a treatment goal.
- Adverse event reporting classified by Clavien-Dindo grading (many studies used this to grade complications).
Key Coverage Criteria
- ICD-10 codes covered if selection criteria are met: N35.010 - N35.92 Urethral stricture
- PAE can be considered in patients with hematuria of prostatic origin as a method of achieving cessation of bleeding. (Level of Evidence: D; strength of recommendation: strong)
- Alpha adrenergic blockers (alfuzosin, doxazosin, silodosin, tamsulosin, and terazosin)
- Aquablation (AquaBeam, water jet hydrodissection)
- Hormonal manipulation (including finasteride, dutasteride, and dutasteride plus tamsulosin)
- Interstitial laser coagulation of the prostate (ILCP)
2 Active Policies
AETNA-CPB-0079 — Benign Prostatic Hyperplasia
HUMANA-BENIGN-PROSTATIC-HYPERPLASIA-TREATMENTS-MA — Benign Prostatic Hyperplasia Treatments - Medicare Advantage
Related Codes
Have a follow-up question?
Ask Verity about documentation requirements, denial risks, or coverage in your state.